AB0486 ONE-YEAR DIRECT COSTS OF BIOLOGICAL THERAPY IN ANKYLOSING SPONDYLITIS AND ITS PREDICTIVE FACTORS: DATA FROM THE MOROCCAN RBSMR REGISTRY
Slah Bahloul(Hôpital El Ayachi), F. Allali(Délégation Paris 5), L. Achemlal, R. Niamane(Hôpital Militaire Avicenne), I. Ghozlani(Régie Autonome Multi Services D'Agadir), Samir Ahid(Mohammed V University), H. Rkain(Mohammed V University), H. Hassikou, R. Bahiri(Centre Hospitalier Universitaire de Rabat-Salé), I. El Bouchti, S. Fellous(Centre Hospitalier Ibn Sina), Taoufik Harzy(Hôpital El Ayachi), Rédouane Abouqal(Mohammed V University), O. Mkinsi(Centre Hospitalier Universitaire Ibn Rochd), Ihsane Hmamouchi(International University of Rabat), A. El Maghraoui
Cited by 2
Related Papers
Why we should definitely include intra-articular hyaluronic acid as a therapeutic option in the management of knee osteoarthritis: Results of an extensive critical literature review
|Seminars in Arthritis and Rheumatism|2018|164
High Prevalence of Hypovitaminosis D in Morocco: Relationship to Lifestyle, Physical Performance, Bone Markers, and Bone Mineral Density
|Seminars in Arthritis and Rheumatism|2008|154
Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor α
|Annals of the Rheumatic Diseases|2003|122
Sarcopenia in rheumatoid arthritis: prevalence, influence of disease activity and associated factors
|Rheumatology International|2017|114